Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Three versus five years of adjuvant imatinib in high-risk operable GIST
NL-OMON53086Phase 3Completed
- Sponsor
- Leiden University Medical Center
- Start
- Mar 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of imatinib in gastrointestinal stromal tumor (GIST) (2 arms), sponsored by Leiden University Medical Center. Primary endpoints: Recurrence-free survival and Progression-free survival. Started Mar 2017; status: completed.
02
Drugs
03
Conditions
gastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on NL-OMON53086.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53086.